Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is [...]
In a recent post by Oncology Nursing News, Dr. Gina D'Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.
Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.
The LRG, in collaboration with the Pediatric & SDH-Deficient GIST Consortium and key opinion leaders among the GIST pathology community (with Dr. Brian Rubin taking the lead), played a significant role in changing CAP Guidelines. CAP Guidelines are protocols for pathologists to instruct them on the process of diagnosing a disease based on tumor tissue samples.
Genetic Testing and SDHx Mutations: What do they have to do with PGL/GIST/Pheos? This webcast highlights how SDHx mutations impact risks for paraganglioma, pheochromocytomas, and GIST, why genetic testing is helpful for any diagnosis [...]
GI Stromal Tumors: A PatholoGIST's Point of View Mutational Testing in GIST Mutational Testing in GIST is a vital component for survival, especially as cancer treatment becomes more individualized. In this webcast, Dr. Chris [...]
How to Make 2/3 = 1 (100%) In a recent discussion about the frequency of mutations in GIST, we noted that the most common mutation is KIT exon 11, which makes up about 2/3 [...]
Role of Mutational Analysis and Next Generation Sequencing in GIST Andrew Rosenberg, MD, Sylvester Comprehensive Cancer Center View all Life Fest 2018 Videos
So, I’ve been told that I have GIST! Life changes suddenly and profoundly when you receive a cancer diagnosis. It’s normal to experience a state of shock, but there is a practical need to [...]
Researchers have developed a test that can accurately identify over 20% of GIST patients that are unlikely to respond to currently approved treatments. In addition, it can identify which patients need a higher dose [...]
